Literature DB >> 20065509

Role of endothelial nitric oxide synthase in aggravation of indomethacin-induced gastric damage in adjuvant arthritic rats.

S Kato1, F Ohkawa, Y Ito, K Amagase, K Takeuchi.   

Abstract

The role of nitric oxide synthase (NOS) isozymes in the aggravation of indomethacin-induced gastric damage in adjuvant arthritic rats was investigated. Two weeks after injection of Freund's complete adjuvant, the animals were given indomethacin, and the stomach was examined for damage 4 h later. Indomethacin caused hemorrhagic lesions in the normal rat stomach, and these lesions were markedly aggravated in arthritic rats. Pretreatment with L-NAME (a nonselective inhibitor of NOS) and aminoguanidine (a relative selective inhibitor of iNOS) did not affect the ulcerogenic response in normal rats but dose-dependently prevented the aggravation of lesions in arthritic rats, but the effect of aminoguanidine was apparently less than that of L-NAME. The increased ulcerogenic response in arthritic rats was significantly suppressed by 1400 W (a selective inhibitor of iNOS) and L-NIO (a selective inhibitor of eNOS) but not by L-NPA (a selective inhibitor of nNOS). The concurrent administration of 1400 W and L-NIO almost totally abolished the aggravation of damage in arthritic rats. The expressions of eNOS and iNOS but not nNOS in the gastric mucosa were clearly enhanced in arthritic rats. Mucosal levels of non-protein sulfhydryls were significantly lower in arthritic rats than those in normal rats. The aggravation of damage in arthritic rats was significantly prevented by glutathione. These results suggest that the increased ulcerogenic response to indomethacin in arthritic rat stomachs is mediated by NO derived from eNOS in addition to iNOS. It is assumed that eNOS/NO may act harmfully on the gastric mucosa of arthritic rats with mucosal SH deficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20065509

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  7 in total

1.  Oxygen/ozone protects the heart from acute myocardial infarction through local increase of eNOS activity and endothelial progenitor cells recruitment.

Authors:  Clara Di Filippo; Margherita Luongo; Raffaele Marfella; Franca Ferraraccio; Biagio Lettieri; Annalisa Capuano; Francesco Rossi; Michele D'Amico
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-08       Impact factor: 3.000

2.  Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions.

Authors:  José Roberto Santin; Isabel Daufenback Machado; Stephen F P Rodrigues; Simone Teixeira; Marcelo N Muscará; Suely Lins Galdino; Ivan da Rocha Pitta; Sandra H P Farsky
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

3.  Preventive Effects of Tocotrienol on Stress-Induced Gastric Mucosal Lesions and Its Relation to Oxidative and Inflammatory Biomarkers.

Authors:  Mohd Fahami Nur Azlina; Yusof Kamisah; Kien Hui Chua; Ibrahim Abdel Aziz Ibrahim; Hj Mohd Saad Qodriyah
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

4.  On the selectivity of neuronal NOS inhibitors.

Authors:  B Pigott; K Bartus; J Garthwaite
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

5.  Panacea seed "Nigella": A review focusing on regenerative effects for gastric ailments.

Authors:  Shahida A Khan; Aziz M Khan; Sajjad Karim; Mohammad Amjad Kamal; Ghazi A Damanhouri; Zeenat Mirza
Journal:  Saudi J Biol Sci       Date:  2014-10-13       Impact factor: 4.219

6.  Acute exercise inhibits gastric emptying of liquids in rats: influence of the NO-cGMP pathway.

Authors:  A K M Cavalcante; R C L Siqueira; V N Feitosa Júnior; C R de Andrade; A A Santos; M T B Silva
Journal:  Braz J Med Biol Res       Date:  2018-10-04       Impact factor: 2.590

7.  Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects.

Authors:  Noriaki Nagai; Fumihiko Ogata; Hiroko Otake; Naohito Kawasaki
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.